Sitemap

Clinical Trials

• Study 10: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (AIEOP-BFM ALL 2017)
• CONNECT 1903: A Pilot and Surgical Study of Larotrectinib for Treatment of Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion
• ReRAD: A Phase II Canadian Paediatric Brain Tumour Consortium Study of Re – Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
• PNOC019/NICHE-HGG: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive
• INFORM2 NivEnt: Phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
• HR-NBM study: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
• INTER-EWING- 1: INTERnational scientific program in clinical research to improve outcomes of newly diagnosed EWING sarcoma – trial 1
• PNOC-022 (DMG-ACT) – A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas including Diffuse Intrinsic Pontine Gliomas at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression.
• SIOPEN SCI Registry: Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement
• LINES: European Low and Intermediate Risk Neuroblastoma (Phase III SIOPEN study)
• TINT: A phase II study of trametinib in paediatric, adolescent and young adult patients with Neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas.
• FaR-RMS: Frontline and Relapse Study in RhabdomyoSarcoma Study
• SJ ELiOT: Phase 1 Evaluation of LY2606368, a CHK inhibitor, in combination with cyclophosphamide or gemcitabine for children & adolescents with recurrent medulloblastoma tumours.
• Pαβlo: Paediatric αβ haploidentical transplantation
• PRISM: PRecISion Medicine for Children with Cancer
• PARC: An international phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults.
• MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia: Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
• LGG-Avastin : A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab (Avastin) for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma
• EuroNet-PHL-C2: European Network of Paediatric Hodgkin Lymphoma Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
• rEECur: An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
• AIM BRAIN: Access to Innovative Molecular Diagnostic Profiling for Paediatric Brain Tumours
• NORTH Trial: A phase II study of Panobinostat in Paediatric, Adolescent and Young Adults with Solid Tumours including Neuroblastoma, Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours
• BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication
• COZMOS: Phase I/Ib trial of Combined 5’azacitidine and carboplatin for recurrent/refractory paediatric brain and solid tumours
• MNP2.0: Molecular Neuropathology 2.0
• Blin-fant Study: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia: A collaborative study of the Interfant network
• Hypermutant Cancers Trial: A Pilot Study of Nivolumab in Paediatric Patients with Hypermutant Cancers
• IntReALL HR 2010: International study for treatment of childhood Relapsed high risk ALL (HR-ALL) 2010: A randomized Phase II Study
• FORUM: Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia – For Omitting Radiotherapy in the Under Majority age